Yan Wu

List of Publications by Year in Descending Order

51 papers	2,081 citations	17 h-index	45 g-index
56 ext. papers	2,781 ext. citations	9.5 avg, IF	4.81 L-index

#	Paper	IF	Citations
51	Oral remdesivir derivative VV116 is a potent inhibitor of respiratory syncytial virus with efficacy in mouse model.. *Signal Transduction and Targeted Therapy*, **2022**, 7, 123	21	2
50	Identification, optimization, and biological evaluation of 3-O-□hacotriosyl ursolic acid derivatives as novel SARS-CoV-2 entry inhibitors by targeting the prefusion state of spike protein.. *European Journal of Medicinal Chemistry*, **2022**, 238, 114426	6.8	2
49	High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors. *Protein and Cell*, **2021**, 12, 877-888	7.2	28
48	Discovery and structural optimization of 3-O-□hacotriosyl oleanane-type triterpenoids as potent entry inhibitors of SARS-CoV-2 virus infections. *European Journal of Medicinal Chemistry*, **2021**, 215, 113242	6.8	5
47	Genomic Analysis of a Novel Phage Infecting the Turkey Pathogen APEC O78 and Its Endolysin Activity. *Viruses*, **2021**, 13,	6.2	3
46	SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target. *Cell Research*, **2021**, 31, 847-860	24.7	24
45	Axial Chiral Binaphthoquinone and Perylenequinones from the Stromata of Are SARS-CoV-2 Entry Inhibitors. *Journal of Natural Products*, **2021**, 84, 436-443	4.9	8
44	Broad-spectrum antivirals of protoporphyrins inhibit the entry of highly pathogenic emerging viruses. *Bioorganic Chemistry*, **2021**, 107, 104619	5.1	5
43	Discovery of SARS-CoV-2-E channel inhibitors as antiviral candidates. *Acta Pharmacologica Sinica*, **2021**,	8	7
42	Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein. *Acta Pharmacologica Sinica*, **2021**,	8	11
41	Atypical TNF-TNFR superfamily binding interface in the GITR-GITRL complex for T´cell activation. *Cell Reports*, **2021**, 36, 109734	10.6	1
40	RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates. *Cell Discovery*, **2021**, 7, 82	22.3	4
39	Genomic, Antimicrobial, and Aphicidal Traits of ATR2, and Its Biocontrol Potential against Ginger Rhizome Rot Disease Caused by .. *Microorganisms*, **2021**, 10,	4.9	1
38	Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension. *Cell Discovery*, **2020**, 6, 96	22.3	50
37	Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. *Nature Structural and Molecular Biology*, **2020**, 27, 529-532	17.6	234
36	A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. *Science*, **2020**, 368, 1274-1278	33.3	682
35	Development of horse neutralizing immunoglobulin and immunoglobulin fragments against Junꢀ virus. *Antiviral Research*, **2020**, 174, 104666	10.8	12

34	Immunoglobulin fragment F(ab')2 against RBD potently neutralizes SARS-CoV-2 in vitro. *Antiviral Research*, **2020**, 182, 104868	10.8	34
33	Structure-Based Modification of an Anti-neuraminidase Human Antibody Restores Protection Efficacy against the Drifted Influenza Virus. *MBio*, **2020**, 11,	7.8	5
32	Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. *Acta Pharmacologica Sinica*, **2020**, 41, 1167-1177	8	161
31	Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2. *Protein and Cell*, **2020**, 11, 723-739	7.2	66
30	Novel spore lytic enzyme from a Bacillus phage leading to spore killing. *Enzyme and Microbial Technology*, **2020**, 142, 109698	3.8	1
29	Comparative Antiviral Efficacy of Viral Protease Inhibitors against the Novel SARS-CoV-2 In Vitro. *Virologica Sinica*, **2020**, 35, 776-784	6.4	15
28	Prevalence and Diversity Analysis of Candidate Prophages to Provide An Understanding on Their Roles in. *Viruses*, **2019**, 11,	6.2	6
27	Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus. *Nature Microbiology*, **2019**, 4, 1231-1241	26.6	22
26	Phage Reduce Stability for Regaining Infectivity during Antagonistic Coevolution with Host Bacterium. *Viruses*, **2019**, 11,	6.2	6
25	Postfusion structure of human-infecting Bourbon virus envelope glycoprotein. *Journal of Structural Biology*, **2019**, 208, 99-106	3.4	0
24	Complete genome sequence of the novel phage vB_BthS-HD29phi infecting Bacillus thuringiensis. *Archives of Virology*, **2019**, 164, 3089-3093	2.6	1
23	Crystal structure of Bacillus thuringiensis Cry7Ca1 toxin active against Locusta migratoria manilensis. *Protein Science*, **2019**, 28, 609-619	6.3	5
22	Characteristics and optimised fermentation of a novel magnetotactic bacterium, Magnetospirillum sp. ME-1. *FEMS Microbiology Letters*, **2018**, 365,	2.9	5
21	Novel neutralizing monoclonal antibodies against Junin virus. *Antiviral Research*, **2018**, 156, 21-28	10.8	9
20	Isolation of A Novel Phage Representing A New Phage Lineage and Characterization of Its Endolysin. *Viruses*, **2018**, 10,	6.2	7
19	Complete Genome Sequence of subsp. Reference Strain YGd22-03. *Genome Announcements*, **2017**, 5,		2
18	Structures of phlebovirus glycoprotein Gn and identification of a neutralizing antibody epitope. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E7564-E7573	11.5	58
17	Synthesis of Sulfo-Sialic Acid Analogues: Potent Neuraminidase Inhibitors in Regards to Anomeric Functionality. *Scientific Reports*, **2017**, 7, 8239	4.9	10

16	Complete Genome Sequence of Serovar rongseni Reference Strain SCG04-02, a Strain Toxic to. *Genome Announcements*, **2017**, 5,		1
15	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses. *Journal of Medicinal Chemistry*, **2016**, 59, 6303-12	8.3	20
14	Changes in the Length of the Neuraminidase Stalk Region Impact H7N9 Virulence in Mice. *Journal of Virology*, **2016**, 90, 2142-9	6.6	23
13	Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor. *Journal of Virology*, **2016**, 90, 10693-10700	6.6	14
12	Effects of actin-like proteins encoded by two Bacillus pumilus phages on unstable lysogeny, revealed by genomic analysis. *Applied and Environmental Microbiology*, **2015**, 81, 339-50	4.8	17
11	Atypical group 1 neuraminidase pH1N1-N1 bound to a group 1 inhibitor. *Protein and Cell*, **2015**, 6, 771-3	7.2	7
10	H7N9: a low pathogenic avian influenza A virus infecting humans. *Current Opinion in Virology*, **2014**, 5, 91-7	7.5	56
9	Bat-derived influenza-like viruses H17N10 and H18N11. *Trends in Microbiology*, **2014**, 22, 183-91	12.4	217
8	Cellular responses in Bacillus thuringiensis CS33 during bacteriophage BtCS33 infection. *Journal of Proteomics*, **2014**, 101, 192-204	3.9	8
7	Genomic analysis of a phage and prophage from a Bacillus thuringiensis strain. *Journal of General Virology*, **2014**, 95, 751-761	4.9	7
6	Structure of influenza virus N7: the last piece of the neuraminidase "jigsaw" puzzle. *Journal of Virology*, **2014**, 88, 9197-207	6.6	33
5	Induced opening of influenza virus neuraminidase N2 150-loop suggests an important role in inhibitor binding. *Scientific Reports*, **2013**, 3, 1551	4.9	58
4	Characterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza viruses. *Cell Research*, **2013**, 23, 1347-55	24.7	77
3	Special features of the 2009 pandemic swine-origin influenza A H1N1 hemagglutinin and neuraminidase. *Science Bulletin*, **2011**, 56, 1747-1752		13
2	Novel Bacillus thuringiensis endotoxin active against Locusta migratoria manilensis. *Applied and Environmental Microbiology*, **2011**, 77, 3227-33	4.8	17
1	Structural basis of diverse peptide accommodation by the rhesus macaque MHC class I molecule Mamu-B*17: insights into immune protection from simian immunodeficiency virus. *Journal of Immunology*, **2011**, 187, 6382-92	5.3	14